KPV Peptide: Benefits for Gut and Skin Inflammation, Dosage Chart, Safety, Legal Status

Key takeaways

• KPV is lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). The fragment keeps the hormone's anti-inflammatory activity and loses its skin-darkening effect, which is why immunologists have studied it since 1989.
• The evidence is mouse, rabbit and cell-culture work: KPV in drinking water or in colon-targeted nanoparticles reduced chemically induced colitis in mice, it quieted inflammatory signaling in human gut and skin cell lines at nanomolar concentrations, and eye drops sped corneal healing in rabbits. There is no published human study of KPV for any condition and no registered trial.
• The doses on seller sites (250 to 500 mcg capsules, 200 to 500 mcg injections, nasal sprays) come from no study. Scaled from the mouse drinking-water studies, a human-equivalent intake would be tens to hundreds of milligrams a day; scaled from the nanoparticle study, under a milligram, but of a targeted formulation no capsule contains.
• The risks are the unknowns: a peptide that dampens NF-kappa-B signaling in immune and gut cells has never been given to a person under observation, FDA's reviewers raised characterization and immunogenicity concerns in July 2026, and the products sold online have no verified content.
• Legal status: never approved; off FDA's Category 2 list since April 15, 2026; recommended 8-6-1 by FDA's advisory committee on July 23, 2026 for wound healing and inflammatory conditions, against the advice of FDA's own staff; no rule published, so no US pharmacy may compound it. Every capsule, spray or vial sold as KPV today is a research chemical.

KPV at a glance

Also called

Lys-Pro-Val, alpha-MSH(11-13), lysine-proline-valine, KPV peptide, KPV acetate

Class

Synthetic three-amino-acid fragment (the C-terminal tripeptide) of alpha-melanocyte-stimulating hormone; keeps the hormone's anti-inflammatory activity and loses its pigment effect; not a hormone and not a growth factor

Route

Sold as oral capsules, nasal sprays and subcutaneous injections, often blended with BPC-157; in animals it was given in drinking water, by gavage inside colon-targeted nanoparticles, by injection, rectally and as eye drops

FDA status

Never approved in any country. Placed on FDA's Category 2 list in 2023-2024 and removed on April 15, 2026 after its nomination was withdrawn. FDA's advisory committee voted 8-6-1 on July 23, 2026 to recommend it for the 503A bulks list for wound healing and inflammatory conditions, over the objection of FDA's own reviewers; no rule has been published as of October 2026, so no US pharmacy may compound it.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Not as a prescription product

Best-studied use

Chemically induced colitis in mice (oral, in drinking water or nanoparticles); irritant ear swelling, peritonitis and brain injury in rodents; corneal wound healing in rabbits; inflammatory signaling in human cell lines. No human study of any kind.

Typical monthly cost (telehealth, 2026)

No legal compounded product exists in the US; whatever a website or clinic charges is for an unapproved research product with no pharmacy, label or recourse behind it

What KPV is and how it is supposed to work

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide cut from the precursor protein proopiomelanocortin. Its famous job is pigment: it binds the melanocortin-1 receptor on melanocytes and darkens skin. Its less famous job is to turn inflammation down, and in 1989 a Dallas physiology group showed that the hormone's last three amino acids, lysine-proline-valine, could do the second job without the first: injected into mice, the tripeptide reduced irritant-induced ear swelling in a dose-related way (Hiltz 1989). That separation is the whole appeal of KPV. Alpha-MSH cannot be a general anti-inflammatory drug because it tans and triggers other melanocortin effects; a fragment that keeps the anti-inflammatory message and drops the pigment one could, in principle (Brzoska 2008).

How the fragment works is better understood than for most peptides sold online, and the details matter for the oral products.

• It does not act through the melanocortin receptors. In a mouse peritonitis model KPV reduced white-cell accumulation; a melanocortin-3/4 receptor antagonist did not block the effect, the peptide did not raise cyclic AMP as receptor agonists do, and it still worked in mice with a nonfunctional melanocortin-1 receptor (Getting 2003). In human keratinocytes, alpha-MSH, KPV and ACTH produced calcium signals and no cyclic AMP rise (Elliott 2004). A Münster group found the same receptor independence in colitis (Kannengiesser 2008).
• It gets into cells through the peptide transporter PepT1, which the small intestine uses to absorb dipeptides and tripeptides from food, and which is barely present in a healthy colon but switched on in the colon lining during inflammatory bowel disease. An Emory group showed that KPV is a PepT1 substrate, that it inhibits NF-kappa-B and MAP-kinase signaling inside gut and immune cells at 10 nanomolar, and that KPV in drinking water reduced two kinds of chemically induced colitis in mice (Dalmasso 2008). The same laboratory later showed that KPV did nothing for colitis-associated tumors in mice lacking PepT1, the clearest demonstration that the transporter is the way in (Viennois 2016).
• Inside the cell it blocks NF-kappa-B, the master switch for inflammatory cytokines such as TNF-alpha and IL-1-beta. Every KPV sales page quotes this mechanism, and in cell culture it is real.

The result is a transporter-dependent, receptor-independent anti-inflammatory effect, strongest where PepT1 is abundant: the small intestine always, and the colon when it is inflamed. That is the rationale for oral KPV in colitis. It is also the reason an oral dose cannot be assumed to reach a tendon, a joint or a patch of eczema.

What the evidence actually shows

Roughly a hundred PubMed records mention the tripeptide by name or sequence, most of them about chemistry or alpha-MSH biology; a couple of dozen tested KPV in a living animal or a disease-relevant cell. None is in a human.

KPV claims, graded by the evidence behind them

Claim	Grade	What the evidence shows	Sources
Reduces chemically induced colitis in mice when taken by mouth	D	KPV in drinking water for 8 days alongside DSS (the concentration is in the paywalled full paper; the same group used 100 micromolar in 2016) reduced histologic damage and inflammatory cytokine expression; a TNBS model gave the same direction. A second laboratory found earlier recovery, faster weight regain and lower colonic myeloperoxidase in DSS and T-cell transfer colitis, and no deaths among KPV-treated mice with a nonfunctional melanocortin-1 receptor.	Dalmasso 2008; Kannengiesser 2008
Works in colon-targeted nanoparticles at far smaller amounts	D	KPV loaded into nanoparticles inside an alginate-chitosan gel protected DSS mice at a concentration the authors put at 12,000-fold below free KPV in solution; a hyaluronic-acid-coated version at 16 mcg/kg a day by gavage for 5 to 6 days reduced mucosal damage and TNF-alpha. A delivery system, not a capsule.	Laroui 2010; Xiao 2017
Prevents colitis-associated colon tumors	D	Mice given a carcinogen plus DSS cycles with 100 micromolar KPV in their water had fewer and smaller tumors and less inflammation; the effect vanished in PepT1-knockout mice. In a genetic tumor model KPV lowered inflammation but not tumor number.	Viennois 2016
Calms inflammation in skin cells and mouse skin	D	Dose-related reduction of irritant ear swelling in mice (1989). In human keratinocytes KPV signals without a cyclic AMP rise; 50 mcg/mL protected a keratinocyte line and a 3-D skin model from particulate-induced cell death and IL-1-beta release. No eczema or psoriasis model of KPV itself.	Hiltz 1989; Elliott 2004; Sung 2025
Stabilizes mast cells or controls histamine	D	No study of KPV on mast cells found. The parent hormone alpha-MSH cut IgE-triggered histamine release from mouse mast cells by about 60 percent, but induced histamine release from human skin mast cells at picomolar concentrations; both effects ran through a receptor KPV does not use.	Adachi 1999; Grützkau 2000
Speeds wound healing	D	Rabbit corneal abrasions treated with KPV eye drops (1 to 10 mg/mL, four times a day) were fully re-epithelialized at 60 hours in 8 of 8 eyes versus 0 of 8 on vehicle; blocking nitric oxide abolished the effect. No animal study of KPV on a skin wound exists; a 2019 review lays out the experiments that would be needed.	Bonfiglio 2006; Böhm 2019
Treats inflammatory bowel disease, eczema, psoriasis or anything else in humans	D	No human study of KPV: none on PubMed or ClinicalTrials.gov as of October 2026. The closest human data are a Phase 2a trial of KdPT, a different tripeptide, as add-on therapy in mild-to-moderate ulcerative colitis, with higher early remission rates against a very high placebo response.	Kucharzik 2017; Kelley Drye 2026
Safe at the doses sold, by any route	D	No human safety data and no formal toxicology study found. FDA staff cited absent human data, inadequate characterization and immunogenicity risk in July 2026; a panelist raised allergenicity and absorption. The committee recommended listing 8-6-1 anyway; no rule has followed.	Healio 2026; Kelley Drye 2026; HPM 2026

The animal literature, in brief

The colitis work is the strongest, and it comes from three independent groups. At Emory, mice drinking 3 percent dextran sulfate sodium, the chemical that strips the colon lining in this model, with KPV added to the water for eight days had less histologic damage and lower cytokine expression than mice drinking DSS alone, and a trinitrobenzene sulfonic acid model pointed the same way (Dalmasso 2008). In Münster, KPV-treated mice recovered earlier from DSS colitis, regained weight faster and had less colonic inflammation; a T-cell transfer model of chronic colitis also improved; and every KPV-treated mouse in a melanocortin-receptor-mutant strain survived a DSS course that killed controls (Kannengiesser 2008). The Emory group then showed that KPV packed into 400-nanometer nanoparticles in a colon-dissolving gel protected DSS mice at a concentration they put at 12,000-fold below free KPV in solution (Laroui 2010), and that a hyaluronic-acid-coated version given by gavage at 16 micrograms per kilogram a day for five to six days reduced mucosal damage and TNF-alpha (Xiao 2017). Mice given a carcinogen and repeated DSS cycles developed fewer and smaller colon tumors with KPV in their water, unless they lacked PepT1 (Viennois 2016).

Read those studies for what they are: acute chemical injuries in young mice, treated from the day the injury starts, with the peptide drunk continuously. Note too what the nanoparticle results imply: free KPV in solution is an inefficient way to reach an inflamed colon, the opposite of what a capsule of free peptide assumes.

The skin and wound data are thinner: the 1989 ear-swelling experiment is an irritant-dermatitis model (Hiltz 1989), the keratinocyte work is in dishes (Elliott 2004) and in a three-dimensional skin model (Sung 2025), and the only wound-healing experiment in a living animal is the rabbit cornea study in the table, in which blocking nitric oxide synthesis abolished the effect (Bonfiglio 2006). No animal study of KPV on a skin wound has been published; the 2019 review by the Münster dermatologists who champion these peptides is a research agenda for one, not a result (Böhm 2019), which matters because wound healing was one of the two uses FDA's committee voted on. The one injected dose in the literature is a single 1 mg/kg abdominal injection after experimental brain injury in mice, which left smaller lesions and less microglial activation (Schaible 2013).

The mast-cell claim

Sellers often call KPV a 'mast cell stabilizer' and recommend it for histamine intolerance or mast cell activation syndrome. We could find no study of KPV on mast cells in PubMed as of October 2026. The claim is borrowed from the parent hormone, and even there the data cut both ways: alpha-MSH reduced IgE-triggered histamine release from mouse bone-marrow mast cells by about 60 percent (Adachi 1999), but in human skin mast cells and skin biopsies, picomolar alpha-MSH induced histamine release (Grützkau 2000). Both effects ran through the melanocortin-1 receptor, which KPV does not use. Nobody knows what KPV does to a human mast cell.

The human evidence, in full

There is none. We searched PubMed and ClinicalTrials.gov on October 9 and 10, 2026 for KPV, Lys-Pro-Val and alpha-MSH(11-13) and found no clinical trial, case series, pharmacokinetic study or registered study of KPV in people. A claim on commercial sites that a 20-person Phase 1 study showed KPV injections to be safe has no registry entry and no publication behind it that we could find.

Two related molecules have human data, and both need to be kept apart from KPV. Afamelanotide is a stabilized analog of the whole 13-amino-acid hormone, delivered as an implant; in two randomized trials (74 patients in Europe, 94 in the United States) it lengthened pain-free sun exposure in people with erythropoietic protoporphyria, a rare photosensitivity disease, and it is approved for that use (Langendonk 2015). It works by activating the melanocortin-1 receptor and darkening skin, exactly the property KPV was isolated to lose. KdPT (lysine-D-proline-threonine) is a tripeptide designed to resemble KPV, with a mirror-image proline and threonine in place of valine, and it is the only member of the family to have reached a controlled human trial: a Phase 2a study in mild-to-moderate ulcerative colitis gave 20, 50 or 100 milligrams by mouth twice a day on top of standard therapy, found higher remission rates than placebo at two and four weeks against a placebo response the authors called very high, and reported good tolerability (Kucharzik 2017). It is a different molecule, developed under a regulatory program, and it is not what is in a KPV capsule.

What FDA's reviewers said in July 2026

KPV was nominated to FDA's list of bulk substances that compounding pharmacies may use, in free-base and acetate forms, with wound healing and inflammatory conditions as the proposed uses, and FDA's Pharmacy Compounding Advisory Committee took it up on July 23, 2026, the same afternoon as BPC-157 and TB-500. FDA's staff recommended against adding any of the seven peptides under review; the objections they repeated across the group, as summarized by the lawyers at Kelley Drye, were insufficient or nonexistent human clinical trial data, inadequate characterization and quality information, uncertainty about the identity and composition of what is actually sold, and safety concerns including immunogenicity (Kelley Drye 2026). The FDA Law Blog notes that the identity and characterization problem ran through every FDA presentation that day (HPM 2026). In the KPV discussion itself, as reported by Healio, a dermatologist on the panel voted no because the clinical indications and the efficacy were not well defined, and raised formulation, chemical characterization, absorption, allergenicity and immunogenicity; a physiatrist voted yes on the view that the panel had seen no significant risk signal and that listing would let the peptide be studied (Healio 2026).

The committee voted 8 to 6 with one abstention, twice, for the free-base and acetate forms. A recommendation is not a rule: FDA must publish a proposed rule, take comments and finalize it, a process Kelley Drye's lawyers expect to take more than a year, and the agency is not obliged to follow the vote. As of our last check of the Federal Register on October 9, 2026, no proposed rule had appeared. The legal tracker will record it when one does.

What you are promised versus what is documented

A typical KPV sales page lists gut healing and 'leaky gut', relief of ulcerative colitis and Crohn's disease, eczema, psoriasis, acne and rosacea, mast cell and histamine disorders, allergies, wound healing and 'systemic inflammation'. The evidence sorts those into three bins.

• Documented in mice, rabbits or cells: less chemically induced colitis in mice; less irritant ear swelling, peritonitis and post-injury brain inflammation in rodents; faster corneal re-epithelialization in rabbits; lower NF-kappa-B activity in human gut, airway and skin cell lines.
• Plausible but untested in people: any effect on ulcerative colitis, Crohn's disease, eczema, psoriasis or skin wounds.
• Not supported by any evidence we could find: mast cell stabilization or histamine control; benefit in acne, rosacea, allergies, autoimmune disease or 'systemic inflammation'; any effect from a nasal spray; any benefit from stacking with BPC-157.

One claim can be settled in KPV's favor: it does not tan. The pigment effect of alpha-MSH needs the receptor-binding core of the hormone, and the tripeptide lacks it (Brzoska 2008).

KPV versus what a gastroenterologist or dermatologist can prescribe

The 2025 American College of Gastroenterology guideline grades each ulcerative colitis option by severity and by the quality of the trials behind it (Rubin 2025). The 2024 American Academy of Dermatology guideline on systemic therapy for adult eczema makes strong recommendations for dupilumab, tralokinumab, abrocitinib, baricitinib and upadacitinib and recommends against systemic corticosteroids (Davis 2024); baricitinib is not FDA-approved for eczema in the United States. The joint AAD and National Psoriasis Foundation guideline covers the biologics for psoriasis and the monitoring they need (Menter 2019). None of those drugs is harmless; most suppress part of the immune system and come with infection warnings, blood tests and follow-up, which is the point: a peptide whose one established action is to dampen NF-kappa-B in immune and epithelial cells would need the same scrutiny before anyone could call it safe, and it has had none. This site does not replace a gastroenterologist or a dermatologist; it is meant to help you ask them better questions.

Dosage: what sellers quote versus what was studied

Where do the seller numbers come from? Not from the mouse studies, as far as we can tell; they look like the BPC-157 chart with the name changed. Our arithmetic, labeled as such: KPV has a molecular weight of about 342, so 100 micromolar is about 34 milligrams per liter. A 25-gram mouse drinks roughly 4 to 5 milliliters a day, which is 140 to 170 micrograms of KPV, or about 5.5 to 7 milligrams per kilogram a day. Scaled to a 70-kilogram adult by body weight that is roughly 380 to 480 milligrams a day; scaled by body surface area, the method FDA's guidance uses for first-in-human estimates, it is about 30 to 40 milligrams a day. A 250 to 500 microgram capsule sits 60 to 160 times below even the surface-area figure. The nanoparticle dose scales the other way: 16 micrograms per kilogram becomes about 1.1 milligrams by weight or about 90 micrograms by surface area, numbers in the range sellers quote, but for a colon-targeted hydrogel nanoparticle that the same laboratory found to be thousands of times more potent than free peptide, and no capsule contains that. The single injected dose in the brain-injury study, 1 milligram per kilogram, becomes 70 milligrams by weight or about 5.7 milligrams by surface area, roughly 10 to 350 times the injected doses on seller charts. None of these conversions is a human dose. They show that the circulating charts match no study by any scaling, and that no scaling substitutes for the pharmacokinetic study nobody has done.

The products are what they are: capsules, usually labeled 500 mcg and sometimes sold as a 'supplement' or blended with BPC-157, never tested for stability, absorption or effect in a person; nasal sprays, with no data by that route and no mechanism that makes a nasal dose relevant to the colon or the skin; and injectable vials of 5 or 10 mg, sold alone or in the KLOW blend our GLOW and KLOW page takes apart. Every one is a research chemical with no pharmacy, no label and no verified content. Our KPV dosage chart sets the studied doses against the seller charts in more detail, and the reconstitution calculator will reproduce any chart's arithmetic, the only part of a chart that can be checked.

Side effects and who should not use it

What is known. Nothing systematic. No human study has recorded adverse events because no human study exists, and we found no formal toxicology study of KPV in PubMed. The mouse studies did not report toxicity and were not designed to find it.

The theoretical risks, which are the ones that matter for a decision:

1. Immune modulation. KPV's one established action is to suppress NF-kappa-B signaling in epithelial and immune cells. Every approved drug that does something comparable carries infection warnings and monitoring requirements; a peptide that does the same with no label has the same theoretical liability and no monitoring.
2. Immunogenicity and allergy. Any peptide, especially an impure one, can provoke antibodies or allergic reactions; FDA's staff raised immunogenicity in July 2026 and a panelist raised allergenicity for KPV specifically (Kelley Drye 2026).
3. Histamine, in an unknown direction. The parent hormone both suppressed and triggered histamine release depending on the mast cells studied, and KPV has not been tested.
4. Unknown long-term effects. The longest animal exposure was about 13 weeks in mice. Nobody has taken KPV for months under observation.
5. The product. No verified identity, potency or sterility, and blends with BPC-157 make any reaction impossible to attribute.

Do not use KPV, or treat it strictly as an unknown, if you: are on prescribed therapy for inflammatory bowel disease, eczema or psoriasis (do not substitute, and tell your clinician if you add anything); are immunosuppressed or have an active infection; have a mast-cell or histamine disorder; are pregnant, trying to conceive or breastfeeding; have a cancer history, since the only tumor data are one mouse model; or are a tested athlete, because an unapproved substance falls under the S0 catch-all of the anti-doping rules. If you develop hives, wheezing, fever, bloody diarrhea or a flare of the disease you took it for, stop and see a clinician the same day.

Legal status in the United States

The regulatory story is in the legal tracker; the short version is this.

• Never approved. KPV has never been a component of an approved drug anywhere, has no USP monograph, and is not on FDA's 503A bulks list, so it fails all three tests that would let a licensed pharmacy compound it.
• Category 2, then off it. FDA sorted KPV into Category 2 with about twenty other peptides in 2023 and 2024, and removed it with eleven others on April 15, 2026 because the nominations had been withdrawn; that ended the safety flag and did not make it compoundable.
• Recommended, not permitted. On July 23, 2026 the advisory committee voted 8-6-1 to recommend KPV, in free-base and acetate forms, for wound healing and inflammatory conditions, over the objection of FDA's reviewers (HPM 2026). FDA must propose, take comments on and finalize a rule first; as of October 2026 none exists, and 'FDA-approved for compounding' is false on both words.
• Research and supplement labels do not change the analysis. FDA's 2026 warning letters to online peptide sellers reject research-use disclaimers on products sold with dosing instructions, and a peptide marketed to treat a disease is a drug, not a dietary supplement. The letters go to sellers, not buyers; possessing KPV is not a crime.

Cost and the prescription question

There is no legal compounded KPV in the United States in October 2026, so there is no legitimate price to quote. What exists is a market of research-grade capsules, sprays and vials, and a layer of clinics and telehealth sites that attach a consultation and a prescription to them. The prescription is cosmetic: it cannot make a non-compoundable substance compoundable, and a pharmacy that fills it is operating outside federal law. What you can actually be prescribed depends on the problem: for ulcerative colitis or Crohn's disease, the guideline-graded therapies above from a gastroenterologist; for eczema or psoriasis, topical treatment and then the biologics and oral agents with randomized-trial evidence from a dermatologist; for a wound that will not heal, a wound clinic, because non-healing wounds usually have a cause that no peptide addresses. The question to ask any provider offering KPV is the tracker's: which pharmacy, in which state, on what legal basis? There is no good answer in 2026.

Women, older adults and athletes

There are no human data of any kind, so none by sex or age. Alpha-MSH biology shifts in pregnancy, and nobody has looked at what a fragment of the hormone does to one; avoid KPV when pregnant, trying to conceive or breastfeeding. For older adults, more infections, more medications and more undiagnosed disease make an unmonitored immune-modulating peptide a worse bet, not a better one. For athletes, KPV is not named on the WADA list, but as an unapproved substance with no medical use it falls under the S0 catch-all, and a product blended with BPC-157 or TB-500 contains compounds athletes have been sanctioned for.

Bottom line

KPV is a well-characterized anti-inflammatory fragment with a real mechanism, a transporter that happens to be switched on in an inflamed colon, and a small, consistent set of mouse colitis studies from independent laboratories. That is a hypothesis worth a human trial, and nobody has run one. The skin, mast-cell and wound claims rest on a 1989 ear-swelling experiment, keratinocyte dishes and rabbit corneas. FDA's reviewers reached the same conclusion in July 2026, and the committee's 8-6 vote the other way changes nothing until a rule is published, which has not happened.

If you have ulcerative colitis, Crohn's disease, eczema or psoriasis, the treatments with evidence are available on prescription today, and the specialists who prescribe them will monitor you. If you buy KPV anyway, you are buying a research capsule or vial at a dose a seller invented, for a use no human study supports, from a supply chain FDA told to stop in 2026.

Frequently asked questions

+−What does KPV peptide do?

KPV is the last three amino acids of alpha-melanocyte-stimulating hormone, a hormone that both darkens skin and calms inflammation. The fragment keeps the anti-inflammatory part and loses the pigment part. In cell cultures it enters cells through the peptide transporter PepT1 and switches off NF-kappa-B, the main signal for inflammatory cytokines; in mice it reduced chemically induced colitis when added to drinking water or packed into colon-targeted nanoparticles. What it does in a person is unknown, because it has never been studied in one.

+−What are the benefits of KPV peptide?

The documented benefits are all in animals and cells: less colitis in mice, less irritant ear swelling and post-injury brain inflammation in rodents, faster corneal healing in rabbits, and quieter inflammatory signaling in human gut, airway and skin cell lines. The benefits on sales pages, for leaky gut, eczema, psoriasis, histamine problems, allergies and wound healing, have no human evidence behind them as of October 2026. No clinical trial of KPV has been published or registered.

+−Is KPV peptide FDA approved or legal in 2026?

KPV has never been approved anywhere, and no licensed US pharmacy may compound it. It came off FDA's Category 2 safety-risk list on April 15, 2026 after its nomination was withdrawn, and FDA's advisory committee voted 8 to 6 with one abstention on July 23, 2026 to recommend adding it to the permitted list for wound healing and inflammatory conditions, against the advice of FDA's own reviewers. FDA has not published a rule, so nothing changed: the capsules, sprays and vials sold online are unapproved drugs, and a prescription cannot make a non-compoundable substance compoundable.

+−Can you take KPV orally, and does it work?

Oral KPV has a real rationale: the peptide is carried into cells by PepT1, a transporter that absorbs dipeptides and tripeptides in the small intestine and is switched on in the colon lining during inflammatory bowel disease, and KPV in mouse drinking water reduced colitis. It has also never been tested in a human by any route. The same laboratory that showed the drinking-water effect later found that free KPV in solution needed roughly 12,000 times the concentration of KPV packed into colon-targeted nanoparticles, which argues against a capsule of free peptide being an efficient way to reach an inflamed colon. Whether a swallowed dose does anything in a person has not been measured.

+−What is the dosage of KPV peptide?

There is no human dose, because there is no human trial. Seller charts list 250 to 500 mcg capsules once or twice a day, 200 to 500 mcg subcutaneous injections, and nasal sprays of 500 to 1,500 mcg a day; none of those figures comes from a study. The 2016 mouse colitis-cancer study used 100 micromolar KPV in drinking water, which by our arithmetic is roughly 5 to 7 mg per kilogram a day, or tens to hundreds of milligrams for an adult depending on how you scale it; a nanoparticle study used 16 mcg per kilogram of a targeted formulation no capsule contains. Our dosage chart article lays the studied doses next to the seller charts.

+−What are the side effects of KPV?

Nobody has recorded them, because no human study exists and we found no formal toxicology study either. The theoretical risks follow from what it does: it suppresses NF-kappa-B signaling in immune and epithelial cells, which is how corticosteroids, JAK inhibitors and biologics work and why those drugs carry infection warnings; FDA's reviewers raised immunogenicity in July 2026 and a panelist raised allergenicity; its effect on human mast cells and histamine is unknown; and the products sold online have no verified content, sterility or dose. There are no long-term human data of any kind.

+−Does KPV help with eczema, psoriasis or acne?

There is no human study of KPV in any skin disease and no animal model of eczema or psoriasis treated with KPV itself. The skin evidence is a 1989 mouse ear-swelling experiment, cell-culture work in human keratinocytes, and a rabbit corneal-wound study. A structurally related tripeptide, KdPT, has been tested in psoriasis models and in a small human colitis trial, but it is a different molecule. Eczema and psoriasis have approved treatments with randomized-trial evidence, including biologics and JAK inhibitors for moderate-to-severe disease, which a dermatologist can prescribe.

+−Is KPV a mast cell stabilizer?

No study has tested KPV on mast cells as far as we can find. The claim is borrowed from the parent hormone, and even there the results conflict: alpha-MSH reduced IgE-triggered histamine release from mouse mast cells by about 60 percent in one study, and induced histamine release from human skin mast cells in another. Both effects ran through the melanocortin-1 receptor, which KPV does not use. Someone with mast cell activation syndrome taking KPV for it is running an uncontrolled experiment on themselves.

+−KPV vs BPC-157: which is better for gut health?

Neither has a human trial for any gut condition, neither can be compounded by a US pharmacy, and both were recommended by the same 8-6-1 committee vote in July 2026 without a rule following. BPC-157 has hundreds of rodent papers, mostly from one laboratory in Zagreb, and three uncontrolled human pilots that are not about the gut; KPV has a handful of mouse colitis papers from three independent groups and a well-described transporter mechanism. Our comparison article goes through both. For ulcerative colitis or Crohn's disease the answer in October 2026 is the treatments a gastroenterologist can prescribe.

+−Does KPV tan your skin like melanotan?

No. Pigmentation needs the receptor-binding core of alpha-MSH, which the tripeptide lacks; the absence of a pigment effect is the reason KPV was isolated as a candidate anti-inflammatory in the first place. Melanotan II and afamelanotide are analogs of the whole hormone and do darken skin.

Sources

1. StudyHiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J 1989;3:2282-4. (1989)
2. StudyGetting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 2003;306:631-7. (2003)
3. StudyElliott RJ et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 2004;122:1010-9. (2004)
4. StudyBonfiglio V et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 2006;83:1366-72. (2006)
5. StudyDalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-78. (2008)
6. StudyKannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:324-31. (2008)
7. ReviewBrzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008;29:581-602. (2008)
8. StudyLaroui H et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010;138:843-53. (2010)
9. StudySchaible EV et al. Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One 2013;8:e71056. (2013)
10. StudyViennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016;2:340-57. (2016)
11. StudyXiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017;25:1628-40. (2017)
12. ReviewBöhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol 2019;28:219-24. (2019)
13. StudySung J et al. Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway. Tissue Cell 2025;95:102837. (2025)
14. StudyAdachi S, Nakano T, Vliagoftis H, Metcalfe DD. Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. J Immunol 1999;163:3363-8. (1999)
15. StudyGrützkau A et al. alpha-Melanocyte stimulating hormone acts as a selective inducer of secretory functions in human mast cells. Biochem Biophys Res Commun 2000;278:14-9. (2000)
16. StudyKucharzik T, Lemmnitz G, Abels C, Maaser C. Tripeptide K(D)PT is well tolerated in mild-to-moderate ulcerative colitis: results from a randomized multicenter study. Inflamm Bowel Dis 2017;23:261-71. (2017)
17. StudyLangendonk JG et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med 2015;373:48-59. (2015)
18. GuidelineRubin DT et al. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol 2025;120:1187-224. (2025)
19. GuidelineDavis DMR et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024;90:e43-56. (2024)
20. GuidelineMenter A et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72. (2019)
21. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c; FDA reviewers opposed all four; identity and characterization concerns ran through every FDA presentation). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
22. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know (proposed uses: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing). July 30, 2026. (2026)
23. NewsBascom E. FDA committee recommends looser restrictions for several peptides (KPV voted 8-6-1 twice, free base and acetate; panelist statements on undefined indications, characterization, absorption, allergenicity and immunogenicity). Healio Endocrine Today, July 24, 2026. (2026)